Akiko Fujii

Associate director, Neuroscience Business Unit

Akiko Fujii

Guaranteeing quality and speed to guide clinical trials to a successful conclusion

Guaranteeing quality and speed to guide clinical trials to a successful conclusion

Linical’s Neuroscience Business Unit has been conducting clinical trials since 2006. This has included trials involving niche patient populations in Alzheimer’s disease, Parkinson’s disease, and intractable neurological diseases. Applying all our accumulated knowledge and experience, we have been addressing the needs of our clients by selecting facilities for implementing trials, enrolling research participants, and collecting data.
Due to our experience and expertise, the monitor leaders (MLs) of this unit are equipped to deal with everything from selecting appropriate trial facilities to responding to compliance surveys. In addition, through training and the sharing of knowledge and experience within the unit, we also have personnel who are well-versed in the specific evaluation scales commonly used in CNS disease and who are capable of holding appropriate discussions with medical specialists in CNS. Our teams are made up of leaders and monitors who are highly competent in this area, and with their up-to-date knowledge and accumulated experience, they can propose the most suitable strategies to meet the demands of our clients.

Making use of our connections with physicians who are key opinion leaders in the area of CNS, together with our experience in conducting clinical trials at many university and core hospitals, the whole of the Neuroscience Business Unit is dedicated to working together to guarantee quality and speed and to guide clinical trials to a successful conclusion. For CNS studies, you can trust Linical for all your clinical development needs, from minor to major disorders.